TheranosticTrials.org

Clinical Trial · NCT04306484

18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions

Overview

Background: 3,4-dihydroxy-6-\[18F\]-fluoro-L-phenylalanine (FDOPA) positron emission tomography (PET) can identify well low and high grade brain tumors. However, increased FDOPA uptake has been reported in non-tumoral brain lesions. The aim was to analyse FDOPA-PET in patients with non-tumoral brain lesions and to compare them with patients with (low and high grade) brain tumors. Methods: retrospective analyse. Patients consecutively recruited with suspected primary brain tumor (based on clinical and MRI findings) referred for FDOPA-PET at Nimes university Hospital between June 2015 and June 2019. FDOPA-PET parameters (maximum and mean lesion standardized uptake values \[SUV\] and ratios comparing lesion with different background uptake SUV) and thresholds were analysed in search for those offering optimal discrimination between non-tumoral and tumoral lesions.

Sponsor

Centre Hospitalier Universitaire de Nīmes

ClinicalTrials.gov

NCT04306484

Drug / Compound

DOPA

Isotope(s):
Target(s):
  • LAT1/LAT2
Ligand Class: Small Molecules

Eligibility

Inclusion

  • presence of defined tumor (histology was required) or non-tumor (diagnosed by histological or other analyses) diagnosis,
  • FDOPA-PET scan \<2 months before surgery or stereotactic biopsy (when performed)
  • clinical and MRI follow-up of \>24 months,

Exclusion

Exclusion criteria not yet provided.